Citation Impact
Citing Papers
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
2017 Standout
Alteration of enzyme specificity by computational loop remodeling and design
2009 StandoutNobel
NK Cell Responsiveness Is Tuned Commensurate with the Number of Inhibitory Receptors for Self-MHC Class I: The Rheostat Model
2009
Antitransgene Rejection Responses Contribute to Attenuated Persistence of Adoptively Transferred CD20/CD19-Specific Chimeric Antigen Receptor Redirected T Cells in Humans
2010
A split, conditionally active mimetic of IL-2 reduces the toxicity of systemic cytokine therapy
2022 StandoutNobel
Interleukin-12: A Cytokine at the Interface of Inflammation and Immunity
1998
Mutagenesis in cultured mammalian cells
1972
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
2013 Standout
The biology of human natural killer-cell subsets
2001 Standout
The role of tumour‐associated macrophages in tumour progression: implications for new anticancer therapies
2002 Standout
Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2015
Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective
2009 Standout
Interleukin-12 and the regulation of innate resistance and adaptive immunity
2003 Standout
Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease
2003 Standout
Anti-Third Party CD8+ CTLs as Potent Veto Cells
2000
Lipopolysaccharide sensing an important factor in the innate immune response to Gram-negative bacterial infections: Benefits and hazards of LPS hypersensitivity
2008 StandoutNobel
Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes
2018 StandoutNobel
Immediate versus deferred empirical antifungal (IDEA) therapy in high-risk patients with febrile neutropenia: a randomized, double-blind, placebo-controlled, multicenter study
2012
The SOS chromotest: a review
1993 Standout
Transplantation tolerance induced by “mega dose” CD34+ cell transplants
2000
Radioimmunotherapy and stem-cell transplantation in the treatment of aggressive B-cell lymphoma
2007
Mice lacking tartrate‐resistant acid phosphatase (Acp 5) have disordered macrophage inflammatory responses and reduced clearance of the pathogen, Staphylococcus aureus
2001 StandoutNobel
Can graft-versus-leukemia reactivity be dissociated from graft-versus-host disease?
2007
Megadose of T cell-depleted bone marrow overcomes MHC barriers in sublethally irradiated mice
1995
Stem cell escalation enables HLA-disparate haematopoietic transplants in leukaemia patients
1999
Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2012
Allogeneic transplantation of blood stem cells: Coming of age?
2001
Defining the Role of mTOR in Cancer
2007 Standout
Repertoire Enhancement with Adoptively Transferred Female Lymphocytes Controls the Growth of Pre-Implanted Murine Prostate Cancer
2012 StandoutNobel
Development of therapeutic antibodies for the treatment of diseases
2020 Standout
Defining trained immunity and its role in health and disease
2020 Standout
Immunological reconstitution after hematopoietic cell transplantation – its relation to the contents of the graft
2008
Diffuse large B-cell lymphoma
2013
A guide to cancer immunotherapy: from T cell basic science to clinical practice
2020 Standout
Single-Agent Pixantrone as a Bridge to Autologous Stem Cell Transplantation in a Patient with Refractory Diffuse Large B-Cell Lymphoma
2017 Standout
Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients: Guidelines of the infectious diseases working party of the German Society of Haematology and Oncology
2009
Chimeric antigen receptor T-cell therapies for lymphoma
2017
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
2008 Standout
Allogeneic Transplant with Reduced Intensity Conditioning Regimens may Overcome the Poor Prognosis of B-Cell Chronic Lymphocytic Leukemia with Unmutated Immunoglobulin Variable Heavy-Chain Gene and Chromosomal Abnormalities (11q− and 17p−)
2005
Coordinating Radiometals of Copper, Gallium, Indium, Yttrium, and Zirconium for PET and SPECT Imaging of Disease
2010 Standout
Molecular and genetic basis of furocoumarin reactions
1976 Standout
Current concepts in the diagnosis and management of cytokine release syndrome
2014 Standout
In Vivo mRNA CAR T Cell Engineering via Targeted Ionizable Lipid Nanoparticles with Extrahepatic Tropism
2023 StandoutNobel
FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma
2018
Eradication of Minimal Residual Disease in B-Cell Chronic Lymphocytic Leukemia After Alemtuzumab Therapy Is Associated With Prolonged Survival
2005
MYC + diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation
2012
Lectins: Carbohydrate-Specific Proteins That Mediate Cellular Recognition
1998 Standout
Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies
2017 StandoutNobel
Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli
2002 Standout
In vivo requirement for RecJ, ExoVII, ExoI, and ExoX in methyl-directed mismatch repair
2001 StandoutNobel
Graft-versus-leukemia effects of transplantation and donor lymphocytes
2008
Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention
2009 Standout
Leukodepleted cellular blood components for prevention of transfusion-associated graft-versus-host disease
1995
Phase II Trial of Single-Agent Temsirolimus (CCI-779) for Relapsed Mantle Cell Lymphoma
2005
Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia
2005
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America
2016 Standout
Successful engraftment of T-cell-depleted haploidentical "three-loci" incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum
1994
Chimeric Antigen Receptor Therapy
2018 Standout
Genetic analysis of the 5-azacytidine sensitivity of Escherichia coli K-12
1987 StandoutNobel
Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants
2002 StandoutScience
IL-12–producing monocytes and HLA-E control HCMV-driven NKG2C+ NK cell expansion
2014
2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host
2013 Standout
Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma
2003
2-Aminopurine
1980
Role of Natural Killer Cell Alloreactivity in HLA-Mismatched Hematopoietic Stem Cell Transplantation
1999
Acute myeloid leukaemia cells secrete a soluble factor that inhibits T and NK cell proliferation but not cytolytic function – implications for the adoptive immunotherapy of leukaemia
2001
Innate or Adaptive Immunity? The Example of Natural Killer Cells
2011 StandoutScience
Ionizable Lipid Nanoparticles with Integrated Immune Checkpoint Inhibition for mRNA CAR T Cell Engineering
2023 StandoutNobel
Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells
2011
Works of B. Glaß being referenced
Self‐tolerance of Human Natural Killer Cells Lacking Self‐HLA‐specific Inhibitory Receptors
2008
Sequential high-dose therapy and autologous stem cell transplantation for treatment of mantle cell lymphoma
1997
Allogeneic hematopoietic cell transplantation following conditioning with90Y-ibritumomab-tiuxetan
2005
Allogeneic transplantation in lymphoma: current status
2007
Reduced-intensity conditioning prior to allogeneic transplantation of hematopoietic stem cells: the need for T cells early after transplantation to induce a graft-versus-lymphoma effect
2004
Allogeneic peripheral blood progenitor cells for treatment of relapse after bone marrow transplantation
1997
Autografting of highly purified peripheral blood progenitor cells following myeloablative therapy in patients with lymphoma: a prospective study of the long-term effects on tumor eradication, reconstitution of hematopoiesis and immune recovery
1999
Early stem cell transplantation for chronic lymphocytic leukaemia: a chance for cure?
1998
Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study
2016
Allogeneic MHC‐mismatched activated natural killer cells administered after bone marrow transplantation provide a strong graft‐versus‐leukaemia effect in mice
1997
Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study
2015
A Prospective, Randomized Multicenter Trial of the Empirical Addition of Antifungal Therapy for Febrile Neutropenic Cancer Patients: Results of the Paul Ehrlich Society for Chemotherapy (PEG) Multicenter Trial II
2006
Current status and future perspectives for yttrium-90 (90Y)-ibritumomab tiuxetan in stem cell transplantation for non-Hodgkin's lymphoma
2007
High lytic activity against human leukemia cells after activation of allogeneic NK cells by IL-12 and IL-2.
1996
Graft-vs-leukemia activity and graft-vs-host disease induced by allogeneic Th1- and Th2-type CD4+ T cells in mice.
2001
Superior antileukemic activity of murine peripheral blood progenitor cell (PBPC) grafts mobilized by G-CSF and stem cell factor (SCF) as compared to G-CSF alone.
1998
Conventional chemoimmunotherapy (R-CHOEP-14) or high-dose therapy (R-Mega-CHOEP) for young, high-risk patients with aggressive B-cell lymphoma: Final results of the randomized Mega-CHOEP trial of the German High-Grade Non-Hodgkin Lymphona Study Group (DSHNHL).
2011
The Study of Gene and Chromosome Mutations in Human and Other Mammalian Cell Cultures
1964
Natural killer cells as effector cells of graft-versus-leukemia activity in a murine transplantation model.
1993
Influence of cell dose and graft-versus-host reactivity on rejection rates after allogeneic bone marrow transplantation
1992
Maintenance with rituximab after autologous stem cell transplantation in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL): CORAL final analysis.
2011